Responses
Clinical and epidemiological research
Extended report
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
Compose a Response to This Article
Other responses
No responses have been published for this article.